在癌症治疗耐药性中PPAR激活的作用:对组合疗法和药物开发的影响
Yanxia Zhang1, Bin Xiao2, Yunduo Liu2
1School of Medicine, The South China University of Technology, Guangzhou, 510006, China; Department of Laboratory Medicine, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, 511518, China.
过度激活的过酶增殖器激活受体 (PPARs) 通过改变细胞代谢和促进生存,促进癌症的治疗耐药性. PPAR抗剂在克服这种抗性以更好地治疗癌症方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 治疗耐药性是癌症治疗的一个重大挑战.
- 过氧体增殖器激活受体 (PPARs) 是细胞过程的关键调节者,在癌症中具有复杂的作用.
- 新出现的证据将PPAR与对各种抗癌疗法的耐药性联系起来.
研究的目的:
- 审查激活PPARs在促进耐化疗,放射疗法,向疗法和免疫疗法的作用.
- 阐明PPARs对癌症治疗耐药性和多药耐药性的机制.
- 讨论PPAR抗剂在克服癌症耐药性的潜力.
主要方法:
- 对调查PPAR和癌症治疗耐药性的研究进行文献综述.
- 分析包括代谢重编程,抗亡,增殖和免疫抑制在内的机制.
- 检查PPAR介导的多药耐药性途径,如药物流量和癌症干细胞维护.
主要成果:
- 激活的PPAR通过代谢重编程,增强抗氧化剂防御,抗亡信号和促进增殖,有助于抵抗.
- PPARs诱导免疫抑制瘤微环境,阻碍免疫疗法.
- PPARs通过药物排放,表皮细胞转变为介质细胞,以及癌症干细胞表型来促进多药性耐药性.
结论:
- 过度激活的PPAR与对各种癌症治疗的耐药性有关.
- 用对抗剂向PPAR可能提供一种扭转治疗耐药性的策略.
- 进一步的研究和PPAR向策略的临床翻译是有必要的,以改善癌症管理.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
